^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TROP2 positive

    i
    Apply
    Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) (NCT06357533)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/11/2024
    Primary completion :
    04/24/2028
    Completion :
    05/24/2030
    PD-L1 • TACSTD2
    |
    TROP2 positive
    |
    Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan) • rilvegostomig (AZD2936)
    NIR Fluorescent Molecular Probe for the Identification of Breast Tissue (NCT05708144)
    Phase N/A
    Xiang'an Hospital of Xiamen University
    Completed
    Last update posted :
    01/01/2024
    Initiation :
    02/17/2023
    Primary completion :
    10/30/2023
    Completion :
    10/30/2023
    TACSTD2
    |
    TROP2 positive
    Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells (NCT02425800)
    Phase N/A
    Wake Forest University Health Sciences
    Completed
    Last update posted :
    09/01/2021
    Initiation :
    07/28/2015
    Primary completion :
    11/05/2018
    Completion :
    08/03/2021
    CTNNB1 • CDH1
    |
    TROP2 positive